Ivermectin Renal Filtration and Excretion
Ivermectin is primarily excreted in the feces, with less than 1% of the administered dose excreted in the urine. 1
Pharmacokinetics of Ivermectin
Absorption and Distribution
- After oral administration, ivermectin plasma concentrations are approximately proportional to the dose 1
- Following a standard high-fat meal, ivermectin bioavailability increases approximately 2.5-fold compared to administration in the fasted state 1
- After single 12-mg doses in fasting healthy volunteers, peak plasma concentrations occur at approximately 4 hours after dosing 1
Metabolism
- Ivermectin is extensively metabolized in the liver 1, 2
- The primary enzyme responsible for ivermectin metabolism is cytochrome P450 3A4 (CYP3A4) 1, 2, 3
- CYP3A5 also contributes to ivermectin metabolism but to a significantly lesser extent 2, 3
- Thirteen different metabolites (M1-M13) have been identified, with three major metabolites (M1, M3, and M6) found in microsomes, hepatocytes, and blood after oral administration 2
- The main human metabolites are:
Elimination
- Ivermectin and/or its metabolites are excreted almost exclusively in the feces over an estimated 12 days 1
- Less than 1% of the administered dose is excreted in the urine 1
- The plasma half-life of ivermectin in humans is approximately 18 hours following oral administration 1
- Some metabolites have longer half-lives than the parent compound, with M1 (54.2 ± 4.7 h) and M4 (57.5 ± 13.2 h) having considerably longer half-lives than ivermectin (38.9 ± 20.8 h) 4
Special Considerations in Specific Populations
Renal Impairment
- Since ivermectin is primarily eliminated through fecal excretion and minimally through renal excretion, dosage adjustments are not required in patients with renal impairment 5
- Ivermectin has limited ovicidal activity, and a second dose is often recommended 14 days after the first dose to ensure complete eradication of parasites 5
Hepatic Impairment
- Patients with severe liver disease may be at higher risk for toxicity as the safety of ivermectin in this population is not well established 6
- The safety and pharmacokinetics of ivermectin among persons with liver disease have been evaluated only after single-dose administration 5
- For persons with severe liver dysfunction, caution should be exercised as metabolism may be impaired 6
Mechanism of Action
- Ivermectin is a member of the avermectin class of broad-spectrum antiparasitic agents 1
- It binds selectively to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells 1, 7
- This binding increases the permeability of the cell membrane to chloride ions, causing hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite 1
- Ivermectin may also interact with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA) 1, 7
- The selective activity of ivermectin is attributable to the fact that some mammals do not have glutamate-gated chloride channels and that ivermectin has a low affinity for mammalian ligand-gated chloride channels 1
- Additionally, ivermectin does not readily cross the blood-brain barrier in humans 1, 7
Clinical Implications
- Ivermectin should be taken with food to increase bioavailability 5
- Adjustments to ivermectin dosing are not required in patients with renal impairment 5
- The safety of multiple doses in patients with severe liver disease is not known 5
- Ivermectin should not be used in children who weigh less than 15 kg due to potential neurotoxicity 5
- There is no role for ivermectin in the treatment of CNS infections as it does not reach sufficient concentrations in cerebrospinal fluid 5
In conclusion, ivermectin undergoes extensive hepatic metabolism via CYP3A4 and is primarily eliminated through fecal excretion, with minimal renal excretion.